KURA - Kura Oncology GAAP EPS of -$0.50 beats by $0.05
2023-11-02 16:29:30 ET
More on Kura Oncology
- Kura's Ziftomenib: The Swiss Army Knife In AML Therapy
- BofA starts Kura at buy, cites revenue potential of lead drug ziftomenib
- Seeking Alpha’s Quant Rating on Kura Oncology
- Historical earnings data for Kura Oncology
For further details see:
Kura Oncology GAAP EPS of -$0.50 beats by $0.05